December 10th 2007
Coronary artery disease is the leading cause of death in patients with diabetes. Platelets play a major role in the pathophysiology and clinical manifestations of ischemic heart disease. It is well known that platelets in diabetic patients are hyperreactive, with exaggerated adhesion, aggregation, and thrombin generation. Aspirin and other antiplatelet agents have been shown to reduce the incidence of ischemic events in patients with and without diabetes, whether or not they have a history of cardiovascular disease. This article reviews the latest recommendations for the use of antiplatelet therapy in the primary and secondary prevention of cardiovascular events in diabetic patients.